Cartesian Therapeutics (RNAC) Enters $130M Private Placement
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Oppenheimer Downgrades Cartesian Therapeutics (RNAC) to Perform
July 2, 2024 11:27 AM EDTOppenheimer analyst Matthew Biegler downgraded Cartesian Therapeutics (NASDAQ: RNAC) from Outperform to Perform.
The analyst comments "Weve been bullish on this nameand while the topline results looked excellent at first glance, we just cant get over the ITT versus per protocol... More
